ACE2 and viral infectious disease: With this regard, TCZ is a good therapeutic option for disrupting the IL-6 amplifier, an IL-6-mediated hyper-inflammatory mechanism that can be triggered by innate immune signaling upon viral infection together with Ang II-AT1R-mediated signaling due to the reduction of Ang II-quencher ACE2.